Paper Details

  1. Home
  2. Paper Details

Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man.

Author: BianchettiG, ChauvinM, GiudicelliJ F, GomeniR, MorselliP L, RicherC, ThuillezC

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Betaxolol was a potent and long-lasting beta-adrenoceptor blocker, more potent than propranolol. It had a long duration of action and a long plasma elimination half-life.
Paper Details　
Original Abstract of the Article :
1 The pharmacological effects and the pharmacokinetics of betaxolol (SL 75212), a new beta-adrenoceptor blocking agent, were compared with those of propranolol and a placebo in a double-blind trial involving six healthy volunteers. 2 Heart rate (HR), myocardial contractile force (MCF), systolic bloo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2125.1980.tb00500.x

データ提供：米国国立医学図書館（NLM）

Betaxolol: A Promising Beta-Adrenoceptor Blocking Agent

This study investigates the pharmacological effects and pharmacokinetics of betaxolol, a new beta-adrenoceptor blocking agent, in humans. The researchers compared the effects of betaxolol to those of propranolol and a placebo in a double-blind trial involving six healthy volunteers. They measured heart rate, myocardial contractile force, blood pressure, and peak expiratory flow rate at rest and during exercise. The study found that betaxolol was a potent and long-lasting beta-adrenoceptor blocker, with a duration of action significantly longer than that of propranolol. The researchers also determined the pharmacokinetic profile of betaxolol, finding that it is absorbed well and has a long half-life.

Betaxolol: A Potent and Long-Lasting Beta-Adrenoceptor Blocking Agent

This study highlights the promise of betaxolol as a potent and long-lasting beta-adrenoceptor blocking agent, offering a valuable treatment option for conditions that benefit from this type of medication. The study demonstrates betaxolol's effectiveness and long duration of action, making it a potential alternative to other beta-blockers. It's like finding a wellspring of water in the desert, providing a long-lasting source of hydration and relief.

What Does This Mean for You?

This research provides valuable information for patients who might benefit from beta-blocker medication. It's essential to discuss your individual needs and potential benefits with your doctor to determine the most appropriate treatment option. Just as a camel relies on its knowledge of the desert to find water, understanding your health conditions and seeking professional guidance is crucial for making informed choices about your care.

Dr.Camel's Conclusion

This study underscores the importance of research in developing new and improved medications, offering valuable insights for patients seeking effective treatment options. The discovery of betaxolol as a potent and long-lasting beta-blocker is a testament to the continuous efforts of scientists to improve healthcare. Just as a camel navigates the desert seeking its next oasis, medicine continues to evolve, offering new and improved solutions for our health and well-being.

Date :
  1. Date Completed 1980-10-24
  2. Date Revised 2019-05-11
Further Info :

Pubmed ID

6104973

DOI: Digital Object Identifier

10.1111/j.1365-2125.1980.tb00500.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.